Apyx Medical study links Renuvion to elastin gains in skin

Apyx Medical Corporation (NASDAQ: APYX) announced results from a prospective clinical study evaluating the effects of its Renuvion helium plasma radiofrequency technology on biological markers of skin quality. The study was published in Plastic and Reconstructive Surgery—Global Open.

The study was conducted at two U.S. sites and evaluated seven patients undergoing facelift surgery. Renuvion treatment was delivered to subdermal tissue, with untreated areas serving as internal controls. Six participants completed the Day 180 visit.

At Day 180, treated tissue showed a 30% increase in elastin fiber density and a 55% increase in elastin staining intensity compared to control tissue. Treated tissue also demonstrated a 34% reduction in inflammation and a 27% increase in the incidence of elastin expression. No significant fibrosis, abnormal vascularization, or epithelial disruption was observed.

All six participants showed improvement in both physician- and patient-assessed aesthetic scores. All participants reported satisfaction with outcomes and said they would recommend the procedure to others.

"These findings provide important new evidence supporting the biological basis for the clinical benefits observed with Renuvion," said Charlie Goodwin, President and Chief Executive Officer of Apyx Medical. "This study provides direct human histological evidence supporting those observations, demonstrating meaningful changes in elastin and inflammation at the tissue level."

The study concluded that Renuvion treatment was well-tolerated and resulted in favorable dermal remodeling. The authors described the findings as direct, quantifiable human evidence that the technology can affect biological markers associated with skin quality.

The information in this article is based on a press release issued by Apyx Medical Corporation.

You May Also Be Interested In

• Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
• Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
• Howard Hughes Holdings CFO to depart in March 2027